Week 8 Discussion Reflection: Your Post Discuss The Followin

Week 8 Discussion Reflectionin Your Post Discuss The Following

Week 8 Discussion Reflectionin Your Post Discuss The Followingbriefl

Week 8 Discussion Reflectionin Your Post, discuss the following: Briefly describe your experience during this course. This can include any type of group of psychotropic medications you consider you will use more in your future practice. Choose one such group of medications covered during this course and describe more fully and reflect on it. Identify the type of medication group of your choice. Describe the basic history of psychotropic medication. Identify your role as a future PMHNP when using this group of psychotropic medication. Describe the purpose and function of the group of medication you chose and why? 3. Reply to your classmates at least 2 on different days of your initial post.

Paper For Above instruction

The course has provided a comprehensive overview of psychiatric-mental health practice, equipping me with the knowledge and skills necessary to become an effective Psychiatric-Mental Health Nurse Practitioner (PMHNP). Throughout this journey, I have gained insights into various psychotropic medication groups, understanding their mechanisms, history, and clinical applications. As I look toward my future practice, I anticipate using several medication groups; however, the antidepressant category, particularly selective serotonin reuptake inhibitors (SSRIs), stands out as especially relevant to my upcoming clinical experiences.

Considering the medication groups covered, I find SSRIs intriguing due to their widespread use and efficacy in treating depression and anxiety disorders. SSRIs, established in the late 1980s with fluoxetine (Prozac), revolutionized mental health treatment by offering a safer, more tolerable alternative to earlier medications like monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). Their development marked a significant milestone in psychopharmacology, emphasizing selective serotonin reuptake inhibition to modulate mood and emotional regulation efficiently. The history of psychotropic medications reflects remarkable progress—from early use of bromides and barbiturates to modern, targeted agents like SSRIs and atypical antipsychotics—highlighting the evolution toward safer, more effective treatment options with fewer side effects.

As a future PMHNP, my role will involve careful assessment of patients' mental health needs, selecting appropriate medications, and monitoring therapeutic outcomes. With SSRIs, my responsibilities include educating patients about medication adherence, potential side effects, and the importance of ongoing evaluation to tailor treatment plans effectively. My role extends beyond prescribing; it encompasses advocating for my patients' overall well-being, addressing obstacles to treatment adherence, and collaborating with interdisciplinary teams to optimize mental health outcomes.

The primary purpose of SSRIs is to alleviate symptoms of depression and anxiety by increasing serotonin levels in the brain, thereby improving mood and emotional stability. Their mechanism involves blocking the reuptake of serotonin into presynaptic neurons, increasing its availability in the synaptic cleft. This enhances serotonergic neurotransmission, which is crucial in regulating mood, anxiety, and other emotional states. The widespread use of SSRIs is due to their effectiveness and relatively favorable side effect profile compared to older antidepressants. They are also versatile, prescribed for a variety of conditions such as obsessive-compulsive disorder, post-traumatic stress disorder, and certain phobias.

Understanding the history, function, and application of SSRIs enhances my ability to provide safe, informed, and patient-centered care as a future PMHNP. This medication group exemplifies the progress in psychopharmacology toward treatments that improve the quality of life for individuals with mental health disorders. As I prepare to enter practice, I am committed to ongoing education and research to stay current with emerging treatments, ensuring that I can offer evidence-based interventions tailored to each patient's unique needs.

References

• Baldwin, D. S., et al. (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A durable guideline. Neuropharmacology, 85, 193-205.
• Blier, P. (2014). The history and mechanism of action of antidepressants. Psychiatry Investigation, 11(1), 1-7.
• Gelenberg, A., et al. (2010). Practice guideline for the treatment of patients with major depressive disorder. American Journal of Psychiatry, 167(10), 1-152.
• Krishnan, R., & Nestadt, G. (2014). Advances in psychopharmacology: The history of antidepressants. Medical Clinics of North America, 98(4), 673-685.
• Thase, M. E., et al. (2013). Pharmacotherapy for depression: History and future directions. Psychiatric Clinics of North America, 36(1), 223-245.
• Fitzgerald, P. B., et al. (2013). New developments in antidepressant drugs. American Journal of Psychiatry, 170(4), 399-409.
• Richter, P., et al. (2019). Selective serotonin reuptake inhibitors: A review of their history, efficacy, and side effects. International Journal of Neuropsychopharmacology, 22(9), 601-608.
• Staton, C. A., & Rancourt, D. (2016). Evolution of psychotropic drug development: From first-generation to second-generation medications. Journal of Psychiatric Research, 78, 44-52.
• Harvey, P., et al. (2017). Clinical guidelines for the management of depression in primary care: Implementation and outcomes. BMC Psychiatry, 17, 367.
• Wilson, C. A., & Fawcett, J. (2018). Pharmacology of antidepressants: Historical perspectives and future trends. Journal of Clinical Psychiatry, 79(5), 25-30.